Literature DB >> 2472115

Antibody-independent, complement-mediated enhancement of HIV-1 infection by mannosidase I and II inhibitors.

D C Montefiori1, W E Robinson, W M Mitchell.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infectivity and cytopathic effect require proper maturation of the viral envelope glycoprotein carbohydrate moieties. We have found that fresh human serum enhances the infectivity of HIV-1 in MT-2 cell infection assays when virus is synthesized in the presence of the mannosidase I inhibitor, 1-deoxymannojirimycin, or the mannosidase II inhibitor, swainsonine, but has no enhancing effect on virus synthesized in the presence of the glucosidase I inhibitors, castanospermine and 1-deoxynojirimycin, or the glucosidase II inhibitor, bromoconduritol. Enhanced infections were characterized by cytopathic effect, antigen synthesis and reverse transcriptase release, all which occurred sooner than in control-infected cultures. This enhancement of infection was also observed in C1q-deficient serum but was not observed in serum that was heat-inactivated or depleted of complement components C3 or factor B, thus suggesting a requirement for the alternate pathway of complement.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472115     DOI: 10.1016/0166-3542(89)90025-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  11 in total

Review 1.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

2.  Infectivities of human and other primate lentiviruses are activated by desialylation of the virion surface.

Authors:  H Hu; T Shioda; C Moriya; X Xin; M K Hasan; K Miyake; T Shimada; Y Nagai
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.

Authors:  R E Means; R C Desrosiers
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line.

Authors:  G S Gras; D Dormont
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21).

Authors:  D C Montefiori; K Stewart; J M Ahearn; J Zhou; J Zhou
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

6.  Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.

Authors:  A Benjouad; J C Gluckman; H Rochat; L Montagnier; E Bahraoui
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge.

Authors:  Craig Miller; Mauren Emanuelli; Elizabeth Fink; Esther Musselman; Ryan Mackie; Ryan Troyer; John Elder; Sue VandeWoude
Journal:  NPJ Vaccines       Date:  2018-04-30       Impact factor: 7.344

Review 8.  Applications of the FIV Model to Study HIV Pathogenesis.

Authors:  Craig Miller; Zaid Abdo; Aaron Ericsson; John Elder; Sue VandeWoude
Journal:  Viruses       Date:  2018-04-20       Impact factor: 5.048

9.  Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.

Authors:  Laura K Pritchard; David J Harvey; Camille Bonomelli; Max Crispin; Katie J Doores
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

10.  Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion.

Authors:  V Boyer; C Desgranges; M A Trabaud; E Fischer; M D Kazatchkine
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.